Preclinical investigation of the topical administration of phenserine: Transdermal flux, cholinesterase inhibition, and cognitive efficacy

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 353-361

  Utsuki, Tadanobu ^a,b   Uchimura, Nao ^c   Irikura, Mitsuru ^c   Moriuchi, Hiroshi ^c,e   Holloway, Harold W ^a   Yu, Qian Sheng ^a   Spangler, Edward L ^d   Mamczarz, Jacek ^d,f   Ingram, Donald K ^b,d   Irie, Tetsumi ^c   Greig, Nigel H ^a,g  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e SOJO UNIVERSITY   (Japan)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (DECYLTHIO)ETHYL]AZACYCLOPENTANE 2 ONE; ACETYLCHOLINESTERASE; CHOLINESTERASE; CYCLOPENTANE DERIVATIVE; FATTY ALCOHOL; HPE 101; PHENSERINE; PROPYLENE GLYCOL; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSION CHAMBER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME INHIBITION; HAIRLESS MOUSE; MALE; MOUSE; NONHUMAN; OINTMENT; PRIORITY JOURNAL; SKIN CULTURE; STRATUM CORNEUM;

ACETYLCHOLINESTERASE; ADMINISTRATION, CUTANEOUS; ANIMALS; AVOIDANCE LEARNING; BUTYRYLCHOLINESTERASE; CEREBRAL CORTEX; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; COGNITION; DIFFUSION CHAMBERS, CULTURE; ELECTROSHOCK; EXCIPIENTS; MALE; MUSCARINIC ANTAGONISTS; OINTMENTS; PHYSOSTIGMINE; RATS; RATS, INBRED F344; SCOPOLAMINE; SKIN ABSORPTION;

EID: 33947375500     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118000     Document Type: Article

References (39)

1. Addicks WJ, Flynn GL, and Weiner N (1987) Validation of a flow-through diffusion cell for use in transdermal research. Pharm Res (NY) 4:337-341.
2. Aungst BJ, Rogers NJ, and Shefter E (1986) Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxide and amides. Int J Pharm 33:225-234.
3. Becker RE, Moriearty P, and Unni L (1991) The second generation of cholinesterase inhibitors: clinical and pharmacological effects, in Cholinergic Basis for Alzheimer's Therapy (Becker RE and Giacobini E eds) pp 263-297, Birkhäuser, Boston, MA.
4. Doucett R, Fisman M, Hachinski VC, and Mersky H (1986) Cell loss from the nucleus basalis of Meynert in Alzheimer's disease. Can J Neurol Sci 13:435-440.
5. Ellman GL, Courtney KD, Andres V Jnr and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
6. Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR, and Elias PM (1995) The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Investig 95:2281-2290.
7. Greig NH, DeMichel E, Holloway HW, Yu QS, Utsuki T, Perry T, Brossi A, Ingram DK, Deutsch J, Lahiri DK, et al. (2000) The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand 176:74-84.
8. Greig NH, Pei XF, Soncrant TT, Ingram DK, and Brossi A (1995) Phenserine and ring C hetero-analogues, drug candidates for the treatment of Alzheimer's disease. Med Res Rev 15:3-31.
9. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR Jr, Canfield CJ, and Burford RG (2005a) Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2:483-492.
10. Greig NH, Sambamurti K, Yu Q-S, Brossi A, Bruinsma GB, and Lahari DK (2005b) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2:281-290.
11. Iijima S, Greig NH, Garofalo P, Spangler EL, Heller B, Brossi A, and Ingram DK (1993) Phenserine, a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology (Berl) 112:415-420.
12. Ingram DK (1988) Complex maze learning in rodents as a model of age-related memory impairment. Neurobiol Aging 9:475-485.
13. Ingram DK, Spangler EL, Iijima S, Kuo H, Bresnahan EL, Greig NH, and London ED (1994) New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. Ann NY Acad Sci 717:16-32.
14. 14C-labeled Tacrolimus (FK506) ointment after a single dermal application to the rat. Xenobiol Metab Dispos 14:1-10.
15. Lahiri DK, Chen D, Maloney B, Holloway H, Yu QS, Utsuki T, Giordano T, Sambamurti K, and Greig NH (2007) The experimental Alzheimer's disease drug posiphen lowers amyloid-β peptide levels in cell culture and mice. J Pharmacol Exp Ther 320:386-396.
16. Lahiri DK, Rogers JT, Greig NH, and Sambamurti K (2004) Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 10:3111-3119.
17. Leo A, Greenberg SM, and Growdon JH (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57:513-533.
18. Madison KC, Swartzendruber DC, Wertz PW, and Dowing DT (1987) Presence of intact intercellular lipid lamellae in the upper layers of the stratum corneum. J Investig Dermatol 88:714-718.
19. Malcolm R and Thomas NT (1995) Clinical Pharmacokinetics Concepts and Applications, 8: Movement through Membranes, pp 109-117, Lippincott Williams & Wilkins, Baltimore, MD.
20. Nakashima M, Zhao MF, Ohya H, Sakurai M, Sasaki H, Matsuyama K, and Ichikawa M (1996) Evaluation of in vivo transdermal absorption of cyclosporin with absorption enhancer using intradermal microdialysis in rats. J Pharm Pharmacol 11:1143-1146.
21. Okuyama H, Iseda Y, Kasai S, Imamori K, Takayama K, and Nagai T (1999) Influence of diisopropyl adipate on percutaneous absorption and subcutaneous tissue penetration of diclofenac from alcoholic gel ointment. J Pharm Sci Technol 59:75-83.
22. Ozawa Y, Yamashita T, Sunara H, and Nadai T (1988) Influence of fatty acid-alcohol ester on percutaneous absorption of hydrocortisone butyrate propionate. Chem Pharm Bull 36:2145-2151.
23. Patel N, Spangler EL, Greig NH, Yu Q-S, Ingram DK, and Meyer RC (1998) Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport 9:171-176.
24. Sambamurti K, Greig NH, and Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1:1-31.
25. Scheuplein RJ and Blank IH (1973) Mechanism of percutaneous absorption. IV. Penetration of nonelectrolytes (alcohols) from aqueous solution and from pure liquids. J Investig Dermatol 60:286-296.
26. Sclafani J, Nightingale J, Liu P, and Kurihara-Bergstrom T (1993) Flow-through system effects on in vitro analysis of transdermal systems. Pharm Res (NY) 10:1521-1526.
27. Selkoe DJ (2005) Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62:192-195.
28. Shaw KT, Utsuki T, Rogers J, Yu Q-S, Sambamurti K, Brossi A, Ge YW, Lahiri DK, and Greig NH (2001) Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98:7605-7610.
29. Smith WP, Christensen MS, Nacht S, and Gans EH (1982) Effect of lipids on the aggregation and permeability of human stratum corneum. J Investig Dermatol 78:7-11.
30. Spangler EL, Rigby P, and Ingram DK (1986) Scopolamine impairs learning performance of rats in a 14-unit T-maze. Pharmacol Biochem Behav 25:673-679.
31. Surber C, Wilhelm K, and Maibach HI (1991) In-vitro skin pharmacokinetics of acitretin. Percutaneous absorption studies in intact and modified skin from three different species using different receptor solutions. J Pharm Pharmacol 43:836-840.
32. Tanzi RE (2005) Tangles and neurodegenerative disease-a surprising twist. N Engl J Med 353:1853-1855.
33. Tregear RT (1966) The permeability of mammalian skin to ions. J Investig Dermatol 46:16-23.
34. Tsuzuki N, Wong O, and Higuchi T (1988) Effect of primary alcohols on percutaneous absorption. Int J Pharm 46:225-234.
35. Whitehouse D, Price DL, and Struble R (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (Wash DC) 215:1237-1239.
36. Yano T, Higo N, Furukawa K, Tsuji M, Noda K, and Otagiri M (1992) Evaluation of a new penetration enhancer 1-[2-(decylthio)ethyl]azacyclopentan-2- one (HPE-101). J Pharmacobiodyn 9:527-533.
37. Yano T, Higo N, Fukuda K, Tsuji M, Noda K, and Otagiri M (1993) Further evaluation of a new penetration enhancer, HPE-101. J Pharm Pharmacol 9:775-778.
38. Yasuno N, Obata Y, Tsuchiya M, Imai K, Arakawa Y, and Takayama K (2001) The effect of N-methyl-2-pyrrolidone on the percutaneous absorption of ethenzamide. J Pharm Sci Technol 61:154-162.
39. Yu Q-S, Holloway HW, Flippen-Anderson JL, Hoffman B, Brossi A, and Greig NH (2001) Methyl analogues of the experimental Alzheimer's drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 44:4062-4071.